BR112016012755A2 - Uso de 4 a 50 mg de naltrexona de liberação sustentada, ou um sal farmaceuticamente aceitável da mesma e 50 a 400mg de bupropiona, ou um sal farmaceuticamente aceitável da mesma - Google Patents
Uso de 4 a 50 mg de naltrexona de liberação sustentada, ou um sal farmaceuticamente aceitável da mesma e 50 a 400mg de bupropiona, ou um sal farmaceuticamente aceitável da mesmaInfo
- Publication number
- BR112016012755A2 BR112016012755A2 BR112016012755A BR112016012755A BR112016012755A2 BR 112016012755 A2 BR112016012755 A2 BR 112016012755A2 BR 112016012755 A BR112016012755 A BR 112016012755A BR 112016012755 A BR112016012755 A BR 112016012755A BR 112016012755 A2 BR112016012755 A2 BR 112016012755A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- bupropion
- mace
- sustained release
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 4
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 title abstract 3
- 229960001058 bupropion Drugs 0.000 title abstract 3
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 title abstract 3
- 229960003086 naltrexone Drugs 0.000 title abstract 3
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
- 230000002411 adverse Effects 0.000 abstract 5
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 4
- 206010033307 Overweight Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000007211 cardiovascular event Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
USOS PARA REDUÇÃO DE EVENTOS ADVERSOS CARDIOVASCULARES MAIORES. O presente Pedido se refere a composições, kits, usos, sistemas e métodos de uso de naltrexona e bupropiona, ou sais farmaceuticamente aceitáveis das mesmas, para reduzir o risco de resultados ou eventos adversos cardiovasculares, incluindo eventos adversos cardiovasculares maiores (MACE) em indivíduos, de preferência aqueles em risco aumentado de resultados cardiovasculares adversos ou MACE que possam estar acima do peso ou obesos. O presente pedido também se refere a composições, kits, usos, sistemas e métodos de uso de naltrexona e bupropiona ou sais farmaceuticamente aceitáveis das mesmas para o tratamento de excesso de peso ou obesidade em indivíduos, de preferência em risco aumentado de resultados cardiovasculares adversos ou MACE, em que o tratamento reduz o risco de MACE.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361913216P | 2013-12-06 | 2013-12-06 | |
US201361914938P | 2013-12-11 | 2013-12-11 | |
US201461984580P | 2014-04-25 | 2014-04-25 | |
US14/322,810 US8969371B1 (en) | 2013-12-06 | 2014-07-02 | Compositions and methods for weight loss in at risk patient populations |
PCT/US2014/068527 WO2015085044A1 (en) | 2013-12-06 | 2014-12-04 | Compositions and methods for reducing major adverse cardiovascular events |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112016012755A2 true BR112016012755A2 (pt) | 2017-08-08 |
Family
ID=52575014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016012755A BR112016012755A2 (pt) | 2013-12-06 | 2014-12-04 | Uso de 4 a 50 mg de naltrexona de liberação sustentada, ou um sal farmaceuticamente aceitável da mesma e 50 a 400mg de bupropiona, ou um sal farmaceuticamente aceitável da mesma |
Country Status (33)
Country | Link |
---|---|
US (8) | US8969371B1 (pt) |
EP (2) | EP3076971B1 (pt) |
JP (2) | JP6665094B2 (pt) |
KR (3) | KR20230152800A (pt) |
CN (3) | CN117159547A (pt) |
AU (1) | AU2014360492A1 (pt) |
BR (1) | BR112016012755A2 (pt) |
CA (1) | CA2932127C (pt) |
CL (1) | CL2016001362A1 (pt) |
CR (1) | CR20160313A (pt) |
CY (1) | CY1125114T1 (pt) |
DK (1) | DK3076971T3 (pt) |
EA (1) | EA201690964A1 (pt) |
EC (1) | ECSP16057765A (pt) |
ES (1) | ES2903391T3 (pt) |
HR (1) | HRP20220058T1 (pt) |
HU (1) | HUE057551T2 (pt) |
IL (3) | IL300870A (pt) |
JO (1) | JOP20140344B1 (pt) |
LT (1) | LT3076971T (pt) |
MX (2) | MX2016007231A (pt) |
PE (1) | PE20161034A1 (pt) |
PL (1) | PL3076971T3 (pt) |
PT (1) | PT3076971T (pt) |
RS (1) | RS62846B1 (pt) |
RU (1) | RU2711638C2 (pt) |
SG (1) | SG10201808055QA (pt) |
SI (1) | SI3076971T1 (pt) |
TN (1) | TN2016000231A1 (pt) |
TW (1) | TWI661826B (pt) |
UY (1) | UY35864A (pt) |
WO (1) | WO2015085044A1 (pt) |
ZA (1) | ZA201603831B (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4343948B2 (ja) | 2003-04-29 | 2009-10-14 | オレキシジェン・セラピューティクス・インコーポレーテッド | 体重減少に影響を及ぼすための組成物 |
CA2630624C (en) | 2005-11-22 | 2013-08-06 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
US8916195B2 (en) * | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
KR20160072276A (ko) | 2006-11-09 | 2016-06-22 | 오렉시젠 세러퓨틱스 인크. | 단위 용량 팩키지 |
CA2725930A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
CN102724878A (zh) | 2010-01-11 | 2012-10-10 | 奥雷西根治疗公司 | 在重度抑郁症患者中提供体重减轻疗法的方法 |
EA201492175A1 (ru) * | 2012-06-06 | 2015-10-30 | Орексиджен Терапьютикс, Инк. | Способы лечения избыточного веса и ожирения |
US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
US9968659B2 (en) | 2016-03-04 | 2018-05-15 | Novo Nordisk A/S | Liraglutide in cardiovascular conditions |
CN109565697B (zh) * | 2016-08-11 | 2021-08-13 | 华为技术有限公司 | 基于非授权频谱的无线通信方法,基站和终端设备 |
WO2023107640A1 (en) * | 2021-12-09 | 2023-06-15 | Incarda Therapeutics, Inc. | Inhaled therapy for cardiac arrhythmia |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4217353A (en) | 1978-05-19 | 1980-08-12 | E. I. Du Pont De Nemours And Company | Method for inducing anorexia |
IL58649A (en) | 1978-11-10 | 1982-04-30 | Beecham Group Ltd | Pharmaceutical dispensing container |
DE3381877D1 (de) | 1982-03-16 | 1990-10-18 | Univ Rockefeller | Verwendung von opium antagonisten zur herstellung von arzneimitteln zur behebung gastro-intestinaler stoerungen. |
GB8613689D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
ES2058272T3 (es) | 1987-05-04 | 1994-11-01 | Lilly Co Eli | Fluoxetina util para el tratamiento de la diabetes. |
US5486362A (en) | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
US5403595A (en) | 1991-05-07 | 1995-04-04 | Dynagen, Inc. | Controlled, sustained release delivery system for smoking cessation |
DE4136215A1 (de) | 1991-11-02 | 1993-05-06 | Ferring Arzneimittel Gmbh, 2300 Kiel, De | Verwendung von opiat-antagonisten zur behandlung von endogener hyperinsulinaemie |
US5512593A (en) | 1993-03-02 | 1996-04-30 | John S. Nagle | Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor |
WO1996009047A1 (en) | 1994-09-19 | 1996-03-28 | The Du Pont Merck Pharmaceutical Company | Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence |
US5627187A (en) | 1995-04-12 | 1997-05-06 | Katz; Bruce E. | 5-FU for treating actinic kerotoses |
GB9517062D0 (en) | 1995-08-18 | 1995-10-25 | Scherer Ltd R P | Pharmaceutical compositions |
EP0795327A1 (en) | 1996-03-13 | 1997-09-17 | Pfizer Inc. | Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin |
US5716976A (en) | 1996-03-13 | 1998-02-10 | Bernstein; Richard K. | Method of treatment for carbohydrate addiction |
JPH11505547A (ja) | 1996-03-13 | 1999-05-21 | エール ユニバーシティ | ナルトレキソン及び関連化合物を用いる禁煙処置 |
WO1997041873A1 (en) | 1996-05-07 | 1997-11-13 | Ergo Research Corporation | Method and composition for the treatment of lipid and glucose metabolism disorders |
EP0915697B1 (en) | 1996-06-28 | 2002-09-18 | Ortho-McNeil Pharmaceutical, Inc. | Anticonvulsant sulfamate derivatives useful in treating obesity |
US5878750A (en) | 1996-11-14 | 1999-03-09 | Clemens; Anton H. | Method of treating the syndrome of coronary heart disease risk factors in humans |
CN1155410C (zh) | 1997-10-03 | 2004-06-30 | 卡里药品公司 | 治疗尼古丁成瘾的含有尼古丁受体拮抗剂和抗抑郁药或抗焦虑药的组合物 |
US6262049B1 (en) | 1997-10-28 | 2001-07-17 | Schering Corporation | Method of reducing nicotine and tobacco craving in mammals |
JP2002501892A (ja) | 1998-01-29 | 2002-01-22 | セプラコア インコーポレーテッド | 光学的に純粋な(−)−ビュープロピオンの薬学的使用 |
US6048322A (en) | 1998-04-15 | 2000-04-11 | Kushida; Clete | Morphometric measurement tool |
US6210716B1 (en) | 1999-02-26 | 2001-04-03 | Andrx Pharmaceuticals, Inc. | Controlled release bupropion formulation |
US6589553B2 (en) | 2001-02-08 | 2003-07-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral dosage form |
NZ514811A (en) | 1999-04-08 | 2005-01-28 | Ortho Mcneil Pharm Inc | Anticonvulsant derivatives useful in reducing blood glucose levels |
US6071918A (en) | 1999-07-21 | 2000-06-06 | Dupont Pharmaceuticals Company | Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence |
US6489350B1 (en) | 1999-09-15 | 2002-12-03 | Elan Pharmaceuticals, Inc. | Methods for treating neuropathic pain using heteroarylmethanesulfonamides |
US6403657B1 (en) | 1999-10-04 | 2002-06-11 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity |
AR031682A1 (es) | 1999-11-19 | 2003-10-01 | Reckitt Benckiser Helthcare Uk | Composiciones farmaceuticas |
US20020055512A1 (en) | 2000-01-21 | 2002-05-09 | Cortendo Ab. | Compositions for delivery of a cortisol antagonist |
GB0001449D0 (en) | 2000-01-21 | 2000-03-08 | Cortendo Ab | Compositions |
CN1406129A (zh) | 2000-01-22 | 2003-03-26 | 艾伯特·舒尔曼 | 用于治疗物质滥用的方法 |
WO2001052851A1 (en) | 2000-01-22 | 2001-07-26 | Albert Shulman | Methods for the treatment of substance abuse |
GEP20053614B (en) | 2000-02-08 | 2005-09-26 | Euro Celtique Sa | Compositions for Oral Administration Containing Opioid Agonist |
US6306436B1 (en) | 2000-04-28 | 2001-10-23 | Teva Pharmaceuticals Usa, Inc. | Stabilized, acid-free formulation for sustained release of bupropion hydrochloride |
US6528520B2 (en) | 2000-08-15 | 2003-03-04 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
ATE396738T1 (de) | 2000-09-18 | 2008-06-15 | Sanos Bioscience As | Verwendung von glp-2-peptiden |
CN100356907C (zh) | 2001-06-08 | 2007-12-26 | 恩德制药公司 | 利用丙烯酸酯聚合物的控释剂型和其制备方法 |
ATE431738T1 (de) | 2001-08-06 | 2009-06-15 | Euro Celtique Sa | Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist |
JP2005501067A (ja) | 2001-08-06 | 2005-01-13 | ユーロ−セルティーク,エス.エイ. | オピオイドの乱用を防ぐための組成物および方法 |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
US7842307B2 (en) | 2001-08-06 | 2010-11-30 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent |
US20030087896A1 (en) | 2001-08-09 | 2003-05-08 | Hillel Glover | Treatment of refractory depression with an opiate antagonist and an antidepressant |
US20040102440A1 (en) | 2002-07-01 | 2004-05-27 | Wong Erik Ho Fong | Method of promoting smoking cessation |
US20040029941A1 (en) | 2002-05-06 | 2004-02-12 | Jennings Julianne E. | Zonisamide use in obesity and eating disorders |
CN1320886C (zh) | 2002-05-17 | 2007-06-13 | 杜克大学 | 安非他酮与抗惊厥药在制备治疗肥胖症的药物的用途 |
CN100411618C (zh) | 2002-05-17 | 2008-08-20 | 迪欧加药品公司 | 有效的选择性阿片受体调制剂化合物的用途 |
US20040005368A1 (en) | 2002-07-01 | 2004-01-08 | Morris Mann | Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite |
US6972291B2 (en) | 2002-07-02 | 2005-12-06 | Bernstein Richard K | Method for reducing food intake |
US7086532B2 (en) | 2003-07-16 | 2006-08-08 | Allergan, Inc. | Titration/compliance pack with increasing doses |
EP1539145A2 (en) | 2002-09-13 | 2005-06-15 | Eisai Co., Ltd. | Method of treating tremors |
US20040192715A1 (en) | 2003-02-05 | 2004-09-30 | Mark Chasin | Methods of administering opioid antagonists and compositions thereof |
US20040204472A1 (en) | 2003-03-04 | 2004-10-14 | Pharmacia Corporation | Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents |
US20050038062A1 (en) | 2003-04-14 | 2005-02-17 | Burns Lindsay H. | Methods and materials for the treatment of pain comprising opioid antagonists |
JP4343948B2 (ja) | 2003-04-29 | 2009-10-14 | オレキシジェン・セラピューティクス・インコーポレーテッド | 体重減少に影響を及ぼすための組成物 |
WO2004100992A2 (en) | 2003-05-16 | 2004-11-25 | Pfizer Products Inc. | Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines |
EP1635832A2 (en) | 2003-06-06 | 2006-03-22 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes |
WO2005032555A2 (en) | 2003-09-25 | 2005-04-14 | Euro-Celtique S.A. | Pharmaceutical combinations of hydrocodone and naltrexone |
US20050096311A1 (en) | 2003-10-30 | 2005-05-05 | Cns Response | Compositions and methods for treatment of nervous system disorders |
US20070149451A1 (en) | 2003-11-17 | 2007-06-28 | Holmes David G | Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent |
JP2007517901A (ja) | 2004-01-13 | 2007-07-05 | デューク・ユニバーシティー | 体重の減少に作用する鎮痙剤及び抗精神病剤の組成物 |
US20050245541A1 (en) | 2004-03-19 | 2005-11-03 | Elliot Ehrich | Methods for treating alcoholism |
CN1968692A (zh) | 2004-05-03 | 2007-05-23 | 杜克大学 | 影响体重减轻的组合物 |
US20050250838A1 (en) | 2004-05-04 | 2005-11-10 | Challapalli Prasad V | Formulation for sustained delivery |
JP2008509142A (ja) | 2004-08-03 | 2008-03-27 | オレキシジェン・セラピューティクス・インコーポレーテッド | 体重減少に影響を及ぼすためのブプロピオンと第2の化合物との組合せ |
WO2007047351A2 (en) | 2005-10-13 | 2007-04-26 | Orexigen Therapeutics, Inc. | Methods for treating hypertension in overweight and obese individuals |
US20070099947A1 (en) | 2005-11-03 | 2007-05-03 | Alkermes, Inc. | Methods and compositions for the treatment of brain reward system disorders by combination therapy |
CA2630624C (en) | 2005-11-22 | 2013-08-06 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
WO2007089318A2 (en) | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
AR058239A1 (es) | 2005-11-28 | 2008-01-23 | Orexigen Therapeutics Inc | Metodos para tratar trastornos de ansiedad |
EP1813276A1 (en) | 2006-01-27 | 2007-08-01 | Euro-Celtique S.A. | Tamper resistant dosage forms |
EP3626236A1 (en) | 2006-06-05 | 2020-03-25 | Nalpropion Pharmaceuticals, Inc. | Sustained release formulation of naltrexone |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
EP2526932B1 (en) | 2006-06-19 | 2017-06-07 | Alpharma Pharmaceuticals LLC | Pharmaceutical composition |
WO2008011150A1 (en) | 2006-07-20 | 2008-01-24 | Somaxon Pharmaceuticals, Inc. | Methods of improving the pharmacokinetics of doxepin |
US8682445B2 (en) | 2006-07-28 | 2014-03-25 | Cyberonics, Inc. | Patient management system for treating depression using an implantable medical device |
KR20160072276A (ko) | 2006-11-09 | 2016-06-22 | 오렉시젠 세러퓨틱스 인크. | 단위 용량 팩키지 |
DK2089005T3 (da) | 2006-11-09 | 2010-07-19 | Orexigen Therapeutics Inc | Lagdelte farmaceutiske formuleringer omfattende et hurtigt opløsende mellemlag |
GB2447949B (en) | 2007-03-29 | 2010-03-31 | Renasci Consultancy Ltd | A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission |
US8318813B2 (en) | 2007-09-13 | 2012-11-27 | Lcs Group, Llc | Method of treating binge eating disorder |
CA2725930A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
CN102724878A (zh) * | 2010-01-11 | 2012-10-10 | 奥雷西根治疗公司 | 在重度抑郁症患者中提供体重减轻疗法的方法 |
TWI536986B (zh) | 2010-12-03 | 2016-06-11 | 歐瑞根治療有限公司 | 降低暴食或強迫進食之方法 |
EA201492175A1 (ru) * | 2012-06-06 | 2015-10-30 | Орексиджен Терапьютикс, Инк. | Способы лечения избыточного веса и ожирения |
US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
-
2014
- 2014-07-02 US US14/322,810 patent/US8969371B1/en active Active
- 2014-12-03 JO JOP/2014/0344A patent/JOP20140344B1/ar active
- 2014-12-04 BR BR112016012755A patent/BR112016012755A2/pt not_active Application Discontinuation
- 2014-12-04 DK DK14867191.0T patent/DK3076971T3/da active
- 2014-12-04 PL PL14867191T patent/PL3076971T3/pl unknown
- 2014-12-04 IL IL300870A patent/IL300870A/en unknown
- 2014-12-04 JP JP2016536659A patent/JP6665094B2/ja active Active
- 2014-12-04 EP EP14867191.0A patent/EP3076971B1/en active Active
- 2014-12-04 CA CA2932127A patent/CA2932127C/en active Active
- 2014-12-04 HU HUE14867191A patent/HUE057551T2/hu unknown
- 2014-12-04 CR CR20160313A patent/CR20160313A/es unknown
- 2014-12-04 RS RS20220039A patent/RS62846B1/sr unknown
- 2014-12-04 WO PCT/US2014/068527 patent/WO2015085044A1/en active Application Filing
- 2014-12-04 CN CN202310405573.1A patent/CN117159547A/zh active Pending
- 2014-12-04 KR KR1020237036479A patent/KR20230152800A/ko not_active Application Discontinuation
- 2014-12-04 KR KR1020227041333A patent/KR20220165791A/ko not_active Application Discontinuation
- 2014-12-04 KR KR1020167017977A patent/KR102472432B1/ko active IP Right Grant
- 2014-12-04 PT PT148671910T patent/PT3076971T/pt unknown
- 2014-12-04 SG SG10201808055QA patent/SG10201808055QA/en unknown
- 2014-12-04 US US15/101,878 patent/US10231962B2/en active Active
- 2014-12-04 ES ES14867191T patent/ES2903391T3/es active Active
- 2014-12-04 EA EA201690964A patent/EA201690964A1/ru unknown
- 2014-12-04 PE PE2016000724A patent/PE20161034A1/es unknown
- 2014-12-04 SI SI201431935T patent/SI3076971T1/sl unknown
- 2014-12-04 MX MX2016007231A patent/MX2016007231A/es unknown
- 2014-12-04 LT LTEPPCT/US2014/068527T patent/LT3076971T/lt unknown
- 2014-12-04 UY UY0001035864A patent/UY35864A/es not_active Application Discontinuation
- 2014-12-04 EP EP21202875.7A patent/EP4005571A1/en active Pending
- 2014-12-04 RU RU2016122483A patent/RU2711638C2/ru active
- 2014-12-04 TN TN2016000231A patent/TN2016000231A1/en unknown
- 2014-12-04 CN CN201480072729.8A patent/CN105899210A/zh active Pending
- 2014-12-04 HR HRP20220058TT patent/HRP20220058T1/hr unknown
- 2014-12-04 AU AU2014360492A patent/AU2014360492A1/en not_active Abandoned
- 2014-12-04 CN CN202111066895.5A patent/CN114404419A/zh active Pending
- 2014-12-05 TW TW103142498A patent/TWI661826B/zh active
-
2015
- 2015-03-02 US US14/635,518 patent/US9119850B2/en active Active
- 2015-08-28 US US14/839,792 patent/US9801875B2/en active Active
-
2016
- 2016-05-30 IL IL245919A patent/IL245919A0/en unknown
- 2016-06-02 MX MX2022001251A patent/MX2022001251A/es unknown
- 2016-06-03 CL CL2016001362A patent/CL2016001362A1/es unknown
- 2016-06-06 ZA ZA2016/03831A patent/ZA201603831B/en unknown
- 2016-07-04 EC ECIEPI201657765A patent/ECSP16057765A/es unknown
-
2017
- 2017-10-05 US US15/725,830 patent/US10231964B2/en active Active
-
2019
- 2019-03-18 US US16/356,663 patent/US10835527B2/en active Active
- 2019-03-18 US US16/356,657 patent/US10828294B2/en active Active
- 2019-12-05 JP JP2019220444A patent/JP7204634B2/ja active Active
-
2020
- 2020-11-16 US US17/099,316 patent/US11998542B2/en active Active
-
2021
- 2021-04-07 IL IL282117A patent/IL282117A/en unknown
-
2022
- 2022-01-19 CY CY20221100048T patent/CY1125114T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016012755A2 (pt) | Uso de 4 a 50 mg de naltrexona de liberação sustentada, ou um sal farmaceuticamente aceitável da mesma e 50 a 400mg de bupropiona, ou um sal farmaceuticamente aceitável da mesma | |
BR112015027282A8 (pt) | formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet | |
AR124497A2 (es) | Métodos para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos métodos, y composición farmacéutica | |
GT200800250A (es) | Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina | |
GT201200313A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
CO6410279A2 (es) | Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente. | |
CL2010001365A1 (es) | Uso de fentermina en combinacion con topiramato para tratar la obesidad mediante una reduccion de peso en una persona. | |
BR112016027041A8 (pt) | combinações farmacêuticas para tratamento do câncer | |
BR112018015718A2 (pt) | utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash) | |
CO7240377A2 (es) | Métodos para el tratamiento del sobrepeso y de la obesidad | |
BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
BR112015027477A8 (pt) | bolus, seus usos, e kit | |
BR112012022243A8 (pt) | Uso de um inibidor de autofagia baseado em tioxantona e de um composto indutor de autofagia para terapia de câncer, composição farmacêutica e kit farmacêutico | |
BR112017002675A2 (pt) | métodos para aperfeiçoar desempenho miocárdico em pacientes de fontan com o uso de composições de udenafila | |
BR112017016497A2 (pt) | composições e métodos para metabolismo muscular melhorado | |
BR112013016615A2 (pt) | uso de dronedarona para a preparação de um medicamento para uso no controle do risco de lesão hepática | |
AR098832A1 (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
CL2017000884A1 (es) | Composición farmacéutica para usarse en el tratamiento o la prevención de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugía de derivación gástrica | |
UY31903A (es) | 7-sulfanilmetil-,7-silfinilmetil-y7-sulfonilmetilindoles sustituidos y el uso de los mismos | |
ECSP12011951A (es) | Uso de una fuente de l3 y/o l5 como vacuna o como diagnóstico para una enfermedad parasitaria | |
BR112013024196A2 (pt) | complexos de gálio, composições farmacêuticas e métodos de uso | |
ES2446494B1 (es) | Aplicación terapéutica de necrostatina-1 en esteatohepatitis | |
ECSP19024033A (es) | Composiciones de tesofensina | |
AR120476A2 (es) | Método para tratar un sujeto que tiene un riesgo de sufrir un evento cardiovascular grave; método para prevenir o retrasar el inicio de dicho evento, método para tratar un sujeto por sobrepeso u obesidad y uso de naltrexona y bupropión para la preparación de un medicamento | |
ES2446215R2 (es) | Aplicación terapéutica de agentes inhibidores de cd44 frente a la leucemia linfoblástica aguda (all) humana. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.21 NA RPI NO 2563 DE 18/02/2020 POR TER SIDO INDEVIDA. |
|
B25A | Requested transfer of rights approved |
Owner name: NALPROPION PHARMACEUTICALS INC. (US) |
|
B25D | Requested change of name of applicant approved |
Owner name: NALPROPION PHARMACEUTICALS LLC (US) |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] |